Unsupervised Analysis of Screen Failure Rates during Clinical Trial Enrollment Practice in a Tertiary Clinical Center of Hematology

Gouin M, Auble H, Moreau P, Chevallier P, Peterlin P, Garnier A, Gastinne T, Touzeau C and Tessoulin B

Centre Hospitalier Universitaire de Nantes, France

^*Correspondance to: Benoit Tessoulin 

 PDF  Full Text Short Communication | Open Access

Abstract:

Purpose: Screen Failures (SF) may occur at various rates during clinical trial enrollment, it may be difficult to pinpoint specific causes. While economic and time are the most used metrics to measure SF impact, it is to note that from a patient point-of-view these SF situations can be particularly difficult to handle. Retrospectively analyzing unenrolled patients may lead to the 
identification of “homogeneous” groups of patients, and help reduce SF rates.
Methods: An unsupervised dimension reduction analysis (Multiple Correspondence Analysis) on patients with SFs was conducted on a 1 year enrollment in our tertiary clinical center of hematology.
Results: Out of 232 patients deemed eligible to be enrolled, 52 patients were considered as SFs (24% SF rate). We highlight with dimension reduction that we can carve out some specific patients’ profiles to be more aware of for enrollment procedures (3 main “paragons” were determined). We also noted an inflation of SF rate for patients with Lymphoid malignancies.
Conclusion: Dimension reduction may help clinical trial teams to narrow down patients that may present with a particular difficult profile to enroll.

Keywords:

Clinical trial; Screen failures; Dimension reduction

Cite the Article:

Gouin M, Auble H, Moreau P, Chevallier P, Peterlin P, Garnier A, et al. Unsupervised Analysis of Screen Failure Rates during Clinical Trial Enrollment Practice in a Tertiary Clinical Center of Hematology. Clin Oncol. 2023;8:1995..